Quick summary
Pramlintide (Symlin) is an FDA-approved synthetic amylin analog co-secreted with insulin by pancreatic beta cells. It reduces post-meal glucose spikes and promotes satiety, and while discontinued from US commerce in 2020, its amylin pathway underpins next-generation agents like cagrilintide.
Overview
Pramlintide (brand: Symlin) is a synthetic analog of human amylin, a hormone co-secreted with insulin by pancreatic beta cells. FDA-approved in 2005 as an adjunct to mealtime insulin for type 1 and type 2 diabetes, it reduces post-meal glucose spikes and promotes satiety. Off-label interest exists for weight management independent of diabetes management.
Mechanism of action
Pramlintide mimics the physiological actions of endogenous amylin at amylin receptors, which are calcitonin receptor/RAMP heterodimers expressed in the area postrema and nucleus tractus solitarius. Activation produces three coordinated effects: slowing of gastric emptying to blunt post-prandial glucose excursions, suppression of inappropriate glucagon secretion from pancreatic alpha cells, and satiety signaling through hypothalamic pathways distinct from those activated by GLP-1 receptor agonists. The dual amylin-and-satiety mechanism complements insulin's glucose-lowering action without increasing hypoglycemia risk on its own, though severe hypoglycemia can occur when mealtime insulin is not reduced appropriately.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| Type 1 diabetes glucose control | subcutaneous | 15–60 mcg | before each major meal | Start at 15 mcg before each meal. Increase by 15 mcg increments every 3 days as tolerated. Target dose 60 mcg per meal. Reduce mealtime insulin by 50% at initiation. |
| Type 2 diabetes glucose control | subcutaneous | 60–120 mcg | before each major meal | Start at 60 mcg before meals. Increase to 120 mcg when no significant nausea for 3–7 days. Reduce mealtime insulin by 50% at initiation. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Multiple randomized controlled trials demonstrate pramlintide lowers HbA1c by 0.4–0.7% and reduces body weight by 1.7 kg (T1D) to 3.7 kg (T2D) versus placebo over 16–52 weeks. It was the first non-insulin therapy approved for type 1 diabetes. Nausea is the primary tolerability hurdle, typically resolving within weeks of titration. Pramlintide was voluntarily discontinued from US commerce by AstraZeneca in 2020; its mechanistic relevance persists as the amylin pathway underpins next-generation agents including cagrilintide and CagriSema.[1][2][3][4]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Pramlintide for synergistic effects.
Legal status
FDA-approved (NDA 021332) for subcutaneous use as an adjunct to mealtime insulin in T1D and T2D. Voluntarily withdrawn from the US market by AstraZeneca circa 2020; no longer commercially available in the US as of 2026. Compounding pharmacy availability varies by jurisdiction.
Sourcing & access
Prescription required
Pramlintide is an FDA-approved prescription medication available through licensed healthcare providers, telehealth platforms, and 503A/503B compounding pharmacies.
Frequently asked questions
Pramlintide (brand: Symlin) is a synthetic analog of human amylin, FDA-approved in 2005 as an adjunct to mealtime insulin for both type 1 and type 2 diabetes. It was the first non-insulin therapy approved for type 1 diabetes.
Pramlintide mimics endogenous amylin at amylin receptors in the brainstem. It produces three coordinated effects: slowing gastric emptying to blunt post-meal glucose spikes, suppressing inappropriate glucagon secretion, and promoting satiety through hypothalamic pathways distinct from GLP-1.
Common side effects include nausea (dose-dependent, typically resolving within weeks), vomiting, anorexia, and headache. Severe hypoglycemia can occur when mealtime insulin is not reduced by 50% at initiation. Pramlintide was voluntarily discontinued from US commerce by AstraZeneca in 2020.
Pramlintide was voluntarily withdrawn from the US market by AstraZeneca circa 2020. It is no longer commercially available in the US as of 2026, though compounding pharmacy availability varies by jurisdiction.
Research references
- A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetesPubMed
- Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trialPubMed
- Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targetsPubMed
- Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitusPubMed